RCI002
/ RudaCure
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 07, 2025
Rci002, a novel trpv1 peptide antagonist, potently alleviates neuropathic pain without hyperthermia
(Neuroscience 2025)
- "This novel mechanism enables significant analgesia without hyperthermic side effects. These results suggest that RCI002 offers a promising new therapeutic strategy for neuropathic pain, combining high efficacy with an improved safety profile as a peptide TRPV1 antagonist."
CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain • TRPV1
September 24, 2023
The Analgesic Effect of RC-0165, a TRPV1 Antagonist, for Osteoarthritis Pain
(ACR Convergence 2023)
- "In vivo, pain-related behavioral effects were compared to RC-0165 and triamcinolone acetonide (TA)as positive control in a MIA-induced OA rat model, which was assessed using Von Frey, Hargreaves, open field, and rotarod tests. The results of our study suggest that RC-0165 may be a promising approach to significantly reduce OA pain compared to TA by suppressing pain signals mediated by TRPV1 effects of RCI002 compare to TA for OA"
Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology • TRPV1
April 27, 2023
The antinociceptive effects of selective TRPV1 antagonist RCI002 against chemotherapy-induced peripheral neuropathy.
(ASCO 2023)
- "TRP vanilloid 1 (TRPV1) may contribute to the development of mechanical allodynia and thermal hyperalgesia after cisplatin or oxaliplatin treatment. Our findings suggest that RCI002 may be a promising approach to reduce paclitaxel-induced hyperexcitability and thereby to reduce neuropathy pain."
Immunology • Neuralgia • Oncology • Pain • Peripheral Neuropathic Pain • TRPV1
1 to 3
Of
3
Go to page
1